Overview

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Status:
Completed
Trial end date:
2016-09-07
Target enrollment:
Participant gender:
Summary
The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Cholinergic Antagonists
Mirabegron
Propiverine
Solifenacin Succinate
Tolterodine Tartrate